Search Tag: #ESCcongress
2024 01 Sep
Adherence to atrial fibrillation (AF) guideline recommendations in clinical practice across Europe was found to be poor, but a structured educational programme for healthcare professionals significantly improved the implementation of heart rhythm control recommendations, according to research presented in a Hot Line session at the ESC Congress...Read more
2023 27 Aug
A recent trial involving all hospitals in London, U.K., reports no disparity in survival at 30 days in patients with resuscitated cardiac arrest who were transported by ambulance to a cardiac arrest centre or the nearest emergency department. These findings were presented during a Hot Line session at the ESC Congress 2023. Sudden cardiac arrest...Read more
2022 29 Aug
Late-breaking research presented at the ESC Congress shows that an artificial intelligence (AI) algorithm accurately estimates the risk of heart disease caused by cumulative exposure to cholesterol and blood pressure levels and the benefits of lowering both, thus providing the information needed to make individual treatment decisions. Atherosclerotic...Read more
2022 29 Aug
The latest research presented at the ESC Congress in Barcelona shows that conventional smartphone-assisted atrial fibrillation (AF) screening more than doubles the detection and treatment rate in older people compared to routine screening. AF is the most common heart rhythm disorder and affects over 40 million people worldwide. People with this...Read more
2022 27 Aug
Findings from the DANFLU-1 trial presented at the ESC Congress in Barcelona show that high-dose influenza vaccination in older adults reduces the risk of death by 49% and the incidence of hospitalisation for influenza or pneumonia by 64% compared with standard-dose vaccination. Several studies have previously investigated the association between...Read more
2022 27 Aug
The latest findings from the PERSPECTIVE trial were presented at the ESC Congress in Barcelona. The study aimed to evaluate sacubitril/valsartan compared with valsartan among symptomatic heart failure patients. The study included 592 patients with symptomatic heart failure. Two hundred and ninety-five patients received 97/103 mg sacubitril/valsartan,...Read more
2021 30 Aug
Late-breaking research from the PRONOUNCE trial was presented in a Hot Line session at ESC Congress 2021. The cardiovascular safety of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the trial was terminated early. Every year, approximately one million men are diagnosed with prostate cancer worldwide. These patients...Read more
2021 28 Aug
In another Hot Line session at the ESC Congress 2021, findings from the ENVISAGE-TAVI AF showed that edoxaban is non-inferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation. The prevalence of pre-existing or new-onset atrial fibrillation after TAVI ranges...Read more
2021 27 Aug
In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction. This was a pooled analysis of two randomised trials that investigated the beneficial effects of...Read more
2021 27 Aug
At the ESC Congress 2021 today, latest insights into the progression to, and management of, heart failure were presented. Dr Carolyn Ho of Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA, discussed the results of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) trial. This trial...Read more
2021 26 Aug
The ESC Congress 2021, the world’s largest cardiovascular event, begins soon. Get ready for the hottest new science in cardiology from August 27-30. During the scientific meeting, all areas of cardiovascular disease will be covered across 15 channels. The spotlight this year will be on Sudden Cardiac Death. In addition, the congress will feature...Read more
2020 01 Sep
Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020. ACE inhibitors and ARBs are commonly taken by heart patients to reduce blood pressure and to...Read more
2020 30 Aug
The main results of the DAPA-CK trial were presented today at ESC Congress 2020. Findings showed that dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. The goal of the DAPA-CKD trial was to...Read more
2020 30 Aug
New findings presented at the ESC Congress show that mavacemten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). To date, the medical treatments for obstructive HCM focus on symptom relief but do not address the underlying causes. These treatments also offer modest efficacy with significant...Read more
2020 29 Aug
In a Hot Line session today at ESC Congress 2020, findings from the EMPEROR-Reduced trial showed that empagiflozin reduces the risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure and a reduced ejection fraction. The findings are published in the New England Journal of Medicine. The clinical trial evaluated...Read more
2020 29 Aug
According to new findings presented at the ESC Congress 2020, influenza and pneumonia vaccinations are associated with fewer hospital deaths in heart failure patients. Approximately 26 million people are affected with heart failure worldwide. It is estimated that one out of five individuals will develop heart failure in their lifetime. Heart failure...Read more
2020 07 May
ESC Congress – the world’s largest cardiovascular event – moves 100% online for the first time in its 70-year history, to create ESC Congress 2020 – Challenging Times, Infinite Possibilities. Mark your calendars now and join the Congress online from Saturday, 29 August to Tuesday, 1 September. The decision by the European Society of Cardiology...Read more
2019 27 Dec
As we move into 2020, here's a quick recap of our most clicked stories in Cardiology in 2019: ORION-10 Trial: Inclisiran Effective at Reducing LDL Findings from the ORION-10 trial presented at the AHA Scientific Session in 2019 showed that twice-yearly injections of inclisiran were effective at reducing LDL cholesterol. ENCOURAGE...Read more
2019 02 Oct
Summary: A presentation of a case study in light of the updated ESC guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. Several new guidelines were released at the European Society of Cardiology (ESC) Congress in Paris, France. These included updated guidelines on lipid control and new guidelines...Read more
2019 04 Sep
New findings presented at the ESC Congress in Paris demonstrated technology that uses artificial intelligence (AI) to identify people at high risk of a fatal heart attack at least five years before it strikes. These findings are published in the European Heart Journal. The technology has been developed by researchers at the University of Oxford....Read more
2019 03 Sep
At the ESC Congress this year, several new guidelines have been released including updated guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. As per the updated guidelines on lipid control , the following are some key recommendations: Low-density lipoprotein (LDL) cholesterol levels should be lowered...Read more
2019 01 Sep
The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris. DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,...Read more
2019 01 Sep
Investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) study at the ESC Congress in Paris. The THEMIS trial evaluated whether adding ticagrelor to aspirin improved...Read more
2019 01 Sep
Findings from the PARAGON-HF trial were presented in the first hot-line session at the ESC Congress today in Paris. Investigators from Brigham and Women's Hospital presented the results of the Prospective Comparison of ARNI with ARB Global Outcome in HF With Preserved Ejection Fraction (PARAGON-HF). This is the largest, randomised clinical trial...Read more
2019 31 Aug
In a very interesting session at the #ESCCongress in Paris on the use of #SoMe in cardiology, Prof. Mamas A. Mamas of the University of Keele talked about ways in which social media can and has changed clinical practice in cardiology. Practice in medicine is led by randomised control trials. All these trials eventually inform clinical guidelines....Read more
2019 31 Aug
New findings from the CHAT-DM study presented at the ESC Congress today report that text message intervention can result in better glycaemic control in patients with diabetes mellitus and coronary heart disease. Findings were just published in Circulation: Cardiovascular Quality and Outcomes. According to the study author Dr. Xiqian Huo of...Read more